
TY  - JOUR
TI  - Acute Coronary Syndromes, Myocardial Infarction, Thrombectomy and Vulnerable Plaque
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 83
IS  - S1
SN  - 1522-1946
UR  - https://doi.org/10.1002/ccd.25491
DO  - doi:10.1002/ccd.25491
SP  - S1
EP  - S247
PY  - 2014
ER  - 

TY  - JOUR
AU  - Palmer, Alan M.
AU  - Alavijeh, Mohammad S.
TI  - Overview of Experimental Models of the Blood-Brain Barrier in CNS Drug Discovery
JO  - Current Protocols in Pharmacology
JA  - Current Protocols in Pharmacology
VL  - 62
IS  - 1
SN  - 1934-8282
UR  - https://doi.org/10.1002/0471141755.ph0715s62
DO  - doi:10.1002/0471141755.ph0715s62
SP  - 7.15.1
EP  - 7.15.30
KW  - blood-brain barrier
KW  - brain disorders
KW  - drug discovery
KW  - neuroscience
KW  - in vivo microdialysis
KW  - MDCK cells
KW  - receptor occupancy
KW  - brain medicines
KW  - brain disorders
PY  - 2013
AB  - Abstract The blood-brain barrier (BBB) is a physical and metabolic entity that isolates the brain from the systemic circulation. The barrier consists of tight junctions between endothelial cells that contain egress transporters and catabolic enzymes. To cross the BBB, a drug must possess the appropriate physicochemical properties to achieve a sufficient time-concentration profile in brain interstitial fluid (ISF). In this overview, we review techniques to measure BBB permeation, which is evidenced by the free concentration of compound in brain ISF over time. We consider a number of measurement techniques, including in vivo microdialysis and brain receptor occupancy following perfusion. Consideration is also given to the endothelial and nonendothelial cell systems used to assess both the BBB permeation of a test compound and its interactions with egress transporters, and computer models employed for predicting passive permeation and the probability of interactions with BBB transporters. Curr. Protoc. Pharmacol. 62:7.15.1-7.15.30. ? 2013 by John Wiley & Sons, Inc.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 60
IS  - s4
SN  - 0002-8614
UR  - https://doi.org/10.1111/j.1532-5415.2012.04000.x
DO  - doi:10.1111/j.1532-5415.2012.04000.x
SP  - S1
EP  - S242
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts and Index of Authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JA  - Pharmacotherapy
VL  - 33
IS  - 10
SN  - 0277-0008
UR  - https://doi.org/10.1002/phar.1356
DO  - doi:10.1002/phar.1356
SP  - e182
EP  - e332
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - International Journal of Laboratory Hematology
VL  - 32
IS  - s1
SN  - 1751-5521
UR  - https://doi.org/10.1111/j.1751-553X.2010.01241.x
DO  - doi:10.1111/j.1751-553X.2010.01241.x
SP  - 71
EP  - 175
PY  - 2010
ER  - 

TY  - JOUR
AU  - Højlund Nielsen, Bodil
AU  - Angelucci, Alessandra
AU  - Scalvenzi, Alessandra
AU  - Forkman, Björn
AU  - Fusi, Francesca
AU  - Tuyttens, Frank
AU  - Houe, Hans
AU  - Blokhuis, Harry
AU  - Tind Sørensen, Jan
AU  - Rothmann, Janne
AU  - Matthews, Lindsay
AU  - Mounier, Luc
AU  - Bertocchi, Luigi
AU  - Marie-Madeleine, Richard
AU  - Donati, Matteo
AU  - Per Peetz, Nielsen
AU  - Salini, Romolo
AU  - de Graaf, Sophie
AU  - Hild, Sophie
AU  - Messori, Stefano
AU  - Nielsen, Søren Saxmose
AU  - Lorenzi, Valentina
AU  - Boivin, Xavier
AU  - Thomsen, Peter T.
C7  - 659E
TI  - Use of animal based measures for the assessment of dairy cow welfare ANIBAM
JO  - EFSA Supporting Publications
JA  - EFSA Supporting Publications
VL  - 11
IS  - 9
SN  - 2397-8325
UR  - https://doi.org/10.2903/sp.efsa.2014.EN-659
DO  - doi:10.2903/sp.efsa.2014.EN-659
SP  - 659E
KW  - Dairy cow
KW  - animal based measure
KW  - animal welfare
PY  - 2014
ER  - 

TY  - JOUR
TI  - Oral presentations
JO  - Clinical Microbiology and Infection
VL  - 14
IS  - s7
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2008.02006.x
DO  - doi:10.1111/j.1469-0691.2008.02006.x
SP  - S1
EP  - S119
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts from the 2004 International Conference on Eating Disorders Finding common ground: Integrating clinical practice and research April 29–May 2, 2004 Caribe Royale All-Suites Resort and Convention Center, Orlando, FL
JO  - International Journal of Eating Disorders
JA  - Int. J. Eat. Disord.
VL  - 35
IS  - 4
SN  - 0276-3478
UR  - https://doi.org/10.1002/eat.20051
DO  - doi:10.1002/eat.20051
SP  - 368
EP  - 503
PY  - 2004
ER  - 

TY  - JOUR
TI  - Annual Meeting of the American Epilepsy Society
JO  - Epilepsia
VL  - 45
IS  - s7
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.0013-9580.2004.t01-21-00001.x
DO  - doi:10.1111/j.0013-9580.2004.t01-21-00001.x
SP  - 1
EP  - 368
PY  - 2004
ER  - 

TY  - JOUR
TI  - POSTER ABSTRACTS
JO  - Australasian Journal on Ageing
VL  - 29
IS  - s1
SN  - 1440-6381
UR  - https://doi.org/10.1111/j.1741-6612.2010.00431.x
DO  - doi:10.1111/j.1741-6612.2010.00431.x
SP  - 27
EP  - 44
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 19
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1002/ejhf.833
DO  - doi:10.1002/ejhf.833
SP  - 5
EP  - 601
PY  - 2017
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - American Journal of Transplantation
VL  - 18
IS  - S4
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.14917
DO  - doi:10.1111/ajt.14917
SP  - 245
EP  - 478
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Urology
VL  - 19
IS  - s1
SN  - 0919-8172
UR  - https://doi.org/10.1111/j.1442-2042.2012.03167.x
DO  - doi:10.1111/j.1442-2042.2012.03167.x
SP  - 5
EP  - 458
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Movement Disorders
JA  - Mov Disord.
VL  - 32
IS  - S2
SN  - 0885-3185
UR  - https://doi.org/10.1002/mds.27087
DO  - doi:10.1002/mds.27087
SP  - S1
EP  - S627
PY  - 2017
ER  - 

TY  - JOUR
TI  - Oral presentations
JO  - Clinical Microbiology and Infection
VL  - 15
IS  - s4
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2009.02857.x
DO  - doi:10.1111/j.1469-0691.2009.02857.x
SP  - S1
EP  - S106
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 17
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1002/ejhf.277
DO  - doi:10.1002/ejhf.277
SP  - 5
EP  - 441
PY  - 2015
ER  - 

TY  - JOUR
TI  - 2017 ACR/ARHP Annual Meeting Abstract Supplement
JO  - Arthritis & Rheumatology
JA  - Arthritis & Rheumatology
VL  - 69
IS  - S10
SN  - 2326-5191
UR  - https://doi.org/10.1002/art.40321
DO  - doi:10.1002/art.40321
SP  - 1
EP  - 4481
PY  - 2017
AB  - Abstract For a searchable version of these abstracts, please visit www.acrabstracts.org.
ER  - 

TY  - JOUR
AU  - Rooney, S.
AU  - Hoffmann, J. J. M. L.
AU  - Cormack, O. M.
AU  - McMahon, C.
TI  - Screening and confirmation of hereditary spherocytosis in children using a CELL-DYN Sapphire haematology analyser
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 37
IS  - 1
SN  - 1751-5521
UR  - https://doi.org/10.1111/ijlh.12245
DO  - doi:10.1111/ijlh.12245
SP  - 98
EP  - 104
KW  - EMA test
KW  - hereditary spherocytosis
KW  - hyperchromic erythrocytes
KW  - spherocytes
PY  - 2015
AB  - Summary Introduction Multidimensional optical scatter of sphered erythrocytes can identify and enumerate hyperchromic erythrocytes, which might be used for hereditary spherocytosis (HS) screening. The flow cytometric eosin-5?-maleimide test (EMA) is highly sensitive and specific for HS as a confirmatory method. The aims of this study were to assess the utility of hyperchromic erythrocytes in HS screening and to evaluate the EMA test performed on CELL-DYN Sapphire analyser compared with the reference method. Methods Blood from 740 paediatric patients presenting at our institution was analysed in reticulocyte mode of the CELL-DYN Sapphire haematology analyser (Abbott Diagnostics) to obtain hyperchromic erythrocyte counts. The EMA test was performed using a flow cytometer as a reference, as well as CELL-DYN Sapphire as an investigational method. Results Hyperchromic erythrocytes were the highest in patients with HS (median 11.5%; range 5.1?29.2%). Patients with autoimmune haemolytic disease had significantly less hyperchromic erythrocytes (median 4.9%; range 0.0?18.3%). Hyperchromic erythrocytes showed a high area under the ROC curve: 0.972. At 4.9% cut-off, hyperchromic erythrocytes detected HS with 96.4% sensitivity and 99.1% specificity. The EMA test on CELL-DYN Sapphire correlated strongly with the reference test and had identical diagnostic power. Stability studies with blood from HS patients showed a significant decrease in hyperchromic erythrocytes after 6 h storage. Conclusions Measurement of hyperchromic erythrocytes is highly sensitive and specific for detecting HS and can be used for rapid and inexpensive screening. If required, the EMA test can be performed on CELL-DYN Sapphire or a standard flow cytometer for confirmation of HS.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Neurourology and Urodynamics
JA  - Neurourol. Urodynam.
VL  - 35
IS  - S4
SN  - 0733-2467
UR  - https://doi.org/10.1002/nau.23074
DO  - doi:10.1002/nau.23074
SP  - S1
EP  - S471
PY  - 2016
ER  - 

TY  - JOUR
C7  - e12751
TI  - Abstracts
JO  - Journal of Sleep Research
JA  - J Sleep Res
VL  - 27
IS  - S1
SN  - 0962-1105
UR  - https://doi.org/10.1111/jsr.12751
DO  - doi:10.1111/jsr.12751
SP  - e12751
PY  - 2018
ER  - 
